TimesSquare Capital Management
TimesSquare U.S. Mid Cap Growth Strategy
US Mid-cap Growth
Mar 2026 → Jun 2026
Our archive holds 2 letters from this strategy, behind 1 investment thesis and positions in 42 companies. Every quote below is copied verbatim from the letter it came from.
2 letters in a year — follow all of TimesSquare Capital Management for every strategy.
What it bought and sold
We trimmed back the position on strength.
We trimmed back the position on strength.
We continued to build our position in Ionis Pharmaceuticals Inc., a commercial-stage biotechnology company focused on neurology and cardiovascular indications.
We meaningfully increased the position size in April and May on stock weakness as our due diligence bolstered our conviction in Snowflake’s position as the center of data gravity.
We have started to scale back the position.
We decided to exit the position due to lackluster booking performance despite significant additions to the sales force.
We exited the position due to the combination of potential AI disruption and the seat-based model's potential challenges.
We added to the position on weakness.
We exited our position following slower-than-expected fourth-quarter results and cautious guidance, attributed to advertising pullbacks by retailers impacted by tariffs.
We added to the position.
We had trimmed back the position prior to Q4 earnings.
We decided to exit this small position on the 35% improvement in its stock price.
We have scaled back the position size.
With investments front-end loaded, DoorDash is positioned for a second-half margin expansion, and that is why we added to the position.